David T Tsai

6720311, Apr 13, 2004

May 14, 2002

10/145682

David Tsai - Irvine CA, 92618

A61K 3808

514 44, 514 6, 514 8, 514 15, 530328, 530400

This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is H-T-F-S-G-V-A-S-V-E and correlates to amino acid no. 300-309 of fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LD of 0. 3-0. 4 M, while the LD for zinc-charged fetuin is 3-10 M.

6737402, May 18, 2004

Jul 9, 2001

09/902208

David Tsai - Irvine CA, 92618

A61K 3816

514 6, 514 8, 514 44, 530400

The present invention provides for an improved method of preparing fetuin by using a chelating agent to remove inorganic ions, such as zinc, calcium, and barium, from fetuin. Then, reloading the ânakedâ fetuin with Zinc Acetate to form a product that is mainly Fetuin-Zinc. This improved method of preparing Fetuin-Zinc or supercharged zinc fetuin increases the effectiveness of inducing apoptosis in cancer cells by three to four times.

7193040, Mar 20, 2007

Feb 5, 2004

10/772537

David Tsai - Irvine CA, US

A61K 38/04
C07K 7/06

530328, 530300

This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu and correlates to amino acid no. 300-309 of fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LDof 0. 3–0. 4 μM while the LDfor zinc-charged fetuin is 3–10 μM.

7223861, May 29, 2007

Oct 26, 2004

10/973631

Shen-Chun Kuo - Union NJ, US
David Jieh-Shyh Tsai - Warren NJ, US
Loc Thanh Tran - Piscataway NJ, US
Pengyi Zhang - Durham NC, US
Andrew D. Jones - Boston MA, US

Schering Corporation - Kenilworth NJ

C07D 239/00

544251

A process for preparing substituted 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine compounds having an aminoalkyl substituent at the 7-position is disclosed, wherein the pyrimidine ring is cyclized using a cyanating agent.

7238662, Jul 3, 2007

Oct 8, 2002

10/267706

David Tsai - Irvine CA, US

Ambryx Biotechnology, Inc. - Riverside CA

A61K 38/08

514 8, 514 2, 514 6

This invention characterizes the selective apoptotic activity of specially prepared Alpha 2-HS glycoprotein and fragments thereof. Specifically, Alpha 2-HS glycoprotein which has been overloaded with zinc, as well as fragnents thereof, selectively induce apoptosis in HT-29 (colon cancer), LNCaP (prostate cancer) and Hep G2 (hepatoma) cells while having no effect on CCD 18 Co (normal colon) cells.

7341724, Mar 11, 2008

Apr 24, 2006

11/409780

David Tsai - Irvine CA, US

A61K 39/00
A61K 38/00
A61K 38/04
C07K 7/00
A61K 49/00

4241851, 530328, 530345

This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Ala Phe Ser Pro Val Ala Ser Val Glu, SEQ ID NO:5. The peptide induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the peptide is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis.

7344721, Mar 18, 2008

Jul 8, 2005

11/178143

David Tsai - Irvine CA, US

A61K 39/00
A61K 38/00
A61K 38/04
C07K 7/00
A61K 49/00

4241851, 530328, 530345

This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His-Thr-Phe-Met-Gy-Val-Val-Ser-Leu-Gly (SEQ ID NO: 3) and correlates to amino acid no. 300-309 of bovine fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LDof 0. 3-0. 4 μM, while the LDfor zinc-charged fetuin is 3-10 μM.

7439361, Oct 21, 2008

Apr 20, 2007

11/788682

Shen-Chun Kuo - Union NJ, US
David Jieh-Shyh Tsai - Warren NJ, US
Loc Thanh Tran - Piscataway NJ, US
Pengyi Zhang - Edison NJ, US
Andrew D. Jones - Boston MA, US

Schering Corporation - Kenilworth NJ

C07D 403/00

544371

A process for preparing substituted 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine compounds having an aminoalkyl substituent at the 7-position is disclosed, wherein the pyrimidine ring is cyclized using a cyanating agent.